Trial Profile
A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Tirofiban (Primary) ; Tirofiban (Primary) ; Eptifibatide; Eptifibatide
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAVI-PCI
- Sponsors Medicure
- 04 Nov 2021 According to a Medicure media release, the key results were shared today at the Transcatheter Cardiovascular.
- 04 Nov 2021 Primary endpoint (The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding) has been met, according to a Medicure media release.
- 04 Nov 2021 Results published in the Medicure Media Release